LAMBERTUCCI, Catia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.462
EU - Europa 4.564
AS - Asia 2.041
SA - Sud America 71
Continente sconosciuto - Info sul continente non disponibili 33
AF - Africa 12
OC - Oceania 7
Totale 17.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.137
CN - Cina 1.448
PL - Polonia 1.255
IT - Italia 910
DE - Germania 554
UA - Ucraina 388
GB - Regno Unito 335
SG - Singapore 326
SE - Svezia 322
CA - Canada 321
FR - Francia 214
RU - Federazione Russa 191
FI - Finlandia 187
TR - Turchia 124
IE - Irlanda 88
BR - Brasile 63
BE - Belgio 34
EU - Europa 33
VN - Vietnam 28
KR - Corea 25
CZ - Repubblica Ceca 21
IN - India 19
HK - Hong Kong 17
NL - Olanda 16
IR - Iran 13
RO - Romania 12
JP - Giappone 9
AT - Austria 7
AU - Australia 5
DK - Danimarca 5
AL - Albania 4
GR - Grecia 4
LB - Libano 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
JO - Giordania 3
MX - Messico 3
TW - Taiwan 3
ZA - Sudafrica 3
DZ - Algeria 2
EC - Ecuador 2
ES - Italia 2
IL - Israele 2
LT - Lituania 2
MA - Marocco 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TN - Tunisia 2
VE - Venezuela 2
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BT - Bhutan 1
BY - Bielorussia 1
CL - Cile 1
CM - Camerun 1
CO - Colombia 1
EE - Estonia 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
KE - Kenya 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 17.190
Salva come PNG Salva come JPEG
Città #
Fairfield 1.293
Woodbridge 1.112
Warsaw 1.098
Jacksonville 961
Chandler 762
Houston 684
Ashburn 675
Seattle 564
Wilmington 516
Ann Arbor 481
Cambridge 440
Boardman 413
Nanjing 315
Toronto 233
Singapore 200
Camerino 196
Kraków 152
San Mateo 143
Dearborn 137
Beijing 133
Lawrence 133
Princeton 133
Istanbul 115
Ogden 108
Columbus 106
Nanchang 102
Düsseldorf 101
Dublin 87
Helsinki 84
Lachine 83
Moscow 78
Shanghai 76
London 70
San Diego 63
Shenyang 63
Kunming 62
New York 62
Tianjin 53
Milan 51
Guangzhou 50
Hebei 42
Jiaxing 42
Centro 38
Brussels 34
Los Angeles 34
Ningbo 30
Jinan 28
Munich 25
Changsha 24
Chicago 24
Dong Ket 23
Hangzhou 23
Wuhan 23
Hefei 22
Norwalk 22
Verona 21
Falls Church 20
Orange 20
Bremen 19
Jinhua 19
Redwood City 19
Philadelphia 18
Zhengzhou 18
Brno 17
Frankfurt am Main 17
Rome 17
Venezia 17
Tappahannock 13
Detroit 12
Nürnberg 12
San Francisco 12
Yiwu 12
Perugia 11
Taizhou 11
Hounslow 10
Indiana 10
New Bedfont 10
Washington 10
Acton 9
Changchun 9
Leawood 9
Osimo 9
Pescara 9
Shenzhen 9
Ardabil 8
Auburn Hills 8
Kilburn 8
Meppel 8
Scafati 8
Seoul 8
São Paulo 8
Buffalo 7
Council Bluffs 7
Hong Kong 7
Kocaeli 7
Lanzhou 7
Scuola 7
Ascoli Piceno 6
Caserta 6
Chengdu 6
Totale 13.137
Salva come PNG Salva come JPEG
Nome #
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 333
Overview on Radiolabel-Free in Vitro Assays for GPCRs 319
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 287
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 269
Pharmacological characterization of the GPR17 receptor dual profile 269
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 260
The G Protein-Coupled Receptor GPR17: Overview and Update 253
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 214
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 212
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 209
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 206
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 198
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 191
GPR17 receptor modulators and their therapeutic implications: review of recent patents 189
Human cytidine deaminase: understanding the catalytic mechanism 184
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 180
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 179
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 175
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 173
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 173
Synthesis and evaluation of hexitol nucleoside congeners as ambiguous nucleosides 172
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 169
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 168
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 166
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 163
New sensible method to quantize the intestinal absorption of receptor ligands 163
Synthesis of a conformationally restricted analogue of paclitaxel 161
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 161
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 161
Biomarkers Mapping in a Neuropathic Pain Mice Model with Sciatic Nerve Chronic Constriction Injury (CCI). 160
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 159
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 158
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 157
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 157
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 156
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 156
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 155
Adenosine deaminase: Functional implications and different classes of inhibitors 154
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 154
A taxane epoxide from taxus wallichiana 153
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 153
Antiviral properties of deazaadenine nucleoside derivatives 153
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 152
Synthesis and NMR-Driven Conformational Analysis of Taxol Analogues Conformationally Constrained on the C13 Side Chain 151
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 151
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 151
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 151
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 150
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 149
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 148
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 148
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 147
Solid phase synthesis and antiprotozoal evaluation of di- and trisubstituted 5 '-carboxamidoadenosine analogues 147
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 146
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 145
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 145
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 143
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 143
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 143
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 142
Coupling of 2,6-disubstituted purines to ribose-modified sugars 141
Adenosine receptor modeling: what does the A2A crystal structure tell us? 140
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 138
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 138
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 135
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 133
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 133
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 131
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 131
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 131
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 130
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 125
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 123
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 123
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 122
Probing ambiguous base-pairs by genetic transformation with XNA templates 121
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 119
The Chemistry and Occurrence of Taxane Derivatives. XXVI. A Reactivity Study on 11(15→1)Abeotaxanes 116
Synthesis of new nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl-D-ribofuranuronamide 115
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands 111
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 111
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 109
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 108
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 108
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 106
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 106
Adenosine receptor agonists:synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives 105
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 105
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 104
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 104
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 101
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 99
Synthetic procedure for the preparation of novel potent and selective A(3) adenosine receptor radioligands 97
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 96
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 93
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 92
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 91
Development of new chromatographic tools based on Adenosine A2A subtype receptor for ligand characterization and screening by FAC-MS 90
Deaza- and deoxyadenosine derivatives: synthesis and inhibition of animal viruses as human infectious models 89
Sintesi di analoghi del paclitaxel vincolati conformazionalmente 89
Totale 15.193
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.724 0 0 0 0 0 304 252 334 231 231 122 250
2020/20213.166 127 254 179 242 161 376 628 71 278 155 439 256
2021/20221.648 185 417 34 40 77 81 94 127 125 176 114 178
2022/20231.815 203 122 46 308 177 259 9 106 316 105 111 53
2023/20241.412 190 79 95 63 66 127 55 91 163 38 42 403
2024/20251.378 191 112 389 227 181 278 0 0 0 0 0 0
Totale 17.568